FirstWord Pharma Publishes CV6’s Clinical Development Funding Announcement
FirstWord Pharma published CV6 Therapeutics’ November 2022 announcement that it had secured $9.2 million to advance its lead oncology drug, CV6-168, toward a first-in-human Phase 1a clinical trial and support further scientific development. The release highlights support from investors in Northern Ireland, the United States and the United Kingdom, alongside research and development grant support from Invest Northern Ireland. It also describes CV6-168’s investigational approach to working alongside established cancer therapies and the planned trial’s focus on safety, dosing and early indications of anti-cancer activity.
More News
View all
News Letter Highlights Invest NI’s Support for CV6’s Cancer Research
The News Letter covers the funding, university collaboration and planned research jobs supporting CV6-168’s development and preparations for its first human trial.
CV6 Therapeutics Secures $9.2m to Progress Novel Cancer Drug to Phase 1a Trial
CV6 Therapeutics (‘CV6’), announces it has secured $9.2m to progress the company’s lead oncology asset CV6-168 into a first-in-human Phase 1a clinical trial and perform further scientific development work.